3 April 2024 - NICE has published final evidence-based recommendations on the use of dostarlimab (Jemperli) in combination with platinum-based chemotherapy for the treatment of adults with advanced or recurrent, high microsatellite instability or mismatch repair deficiency endometrial cancer.

Dostarlimab, when used in combination with platinum-based chemotherapy, is recommended for the treatment of adults with primary advanced or recurrent, high microsatellite instability or mismatch repair deficiency endometrial cancer who are candidates for systemic therapy. 

It is only recommended if the conditions in the managed access agreement for dostarlimab are followed.

Read NICE technology appraisal guidance